CLSA: MGM CHINA (02282) Q3 property EBITDA beats expectations; maintain "Outperform" rating with target price of HK$13.8
The company's third-quarter property EBITDA increased by 1% year-on-year to HK$2.394 billion, beating the market consensus median and the firm's forecast by 6% each.
CLSA issued a research report maintaining its "Outperform" rating on MGM CHINA (02282) with a target price of HK$13.8. Benefiting from better-than-expected revenue market share, the company's Q3 property EBITDA rose 1% year-on-year to HK$2.394 billion, beating the median market expectation and the bank's forecast by 6% each. The bank estimates that the above-normal VIP room win rate contributed approximately HK$132 million to EBITDA.
The bank noted that after MGM CHINA completed the acquisition of the mainland hotel management business, that business contributed revenue of HK$31 million and EBITDA of approximately HK$7 million in Q3. Overall property EBITDA margin narrowed by 1.1 percentage points year-on-year to 26.8% in Q3.
Related Articles

Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.
MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.

KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.
Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.

MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.
KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.






